Hetero Labs Valsartan NDMA Recall Settlement Get Refund for Contaminated Pills

Valsartan is a widely used blood-pressure drug in the ARB (angiotensin II receptor blocker) family, and after the brand-name version (Diovan) lost patent protection, many U.S. prescriptions shifted to lower-cost generics made with globally sourced active ingredients. In 2018, the FDA began announcing large recalls of certain generic ARBs after finding contamination with NDMA (N-nitrosodimethylamine), a “probable human carcinogen,” which regulators said could form unintentionally during certain manufacturing steps. The settlement described here focuses on generic valsartan tied to Hetero Labs’ manufacturing process and distributed in the U.S. through Camber Pharmaceuticals, covering retail purchases made during a narrow window (May 1 to July 31, 2018). The lawsuit was filed as an “economic loss” class action—meaning it seeks refunds for money paid for a medication that was allegedly not what consumers bargained for because it was contaminated and later recalled, rather than compensation for medical injuries. A federal judge in New Jersey overseeing the broader ARB litigation granted preliminary approval to a settlement that would reimburse eligible consumers and third-party payors who bought the covered valsartan, with claim forms expected by April 2, 2026 and a filing deadline of June 2, 2026. Its significance is that it is one of the first major class-wide settlements to advance within the larger MDL (multidistrict litigation) consolidating hundreds of related cases, while separate personal-injury lawsuits—filed by people who developed cancers they attribute to NDMA exposure—continue on a different track and are not resolved by this refund settlement. More broadly, the case sits within ongoing scrutiny of the generic drug supply chain, where cost pressure, overseas manufacturing, and complex chemistry can create quality-control risks that only become visible through testing and FDA surveillance. The FDA’s recall authority and its published lists of affected lots/manufacturers are central tools in these events, and the ARB recalls also extended beyond valsartan to related drugs like losartan and irbesartan, spawning similar claims and parallel settlement “tracks” for different manufacturers. Together, these cases underscore how contamination issues can trigger both regulatory action (recalls and heightened oversight) and layered litigation that separates consumer refund claims from higher-stakes injury claims in the same nationwide proceeding